Search research articles
Contact Us
Filters
Showing results (361-370 of 487) with videos related to
Page
of 49
Sort By:
Nature Medicine
|
August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.
Cancers
|
May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
Anthony P Conley, Wei-Lien Wang, John A Livingston, et al.
Cancer Chemotherapy and Pharmacology
|
June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Journal for Immunotherapy of Cancer
|
April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Scientific Reports
|
November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
Vikas Dembla, Roman Groisberg, Ken Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Cancer Research Communications
|
December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Pashtoon M Kasi, Jessica K Lee, Lincoln W Pasquina, et al.
Page
of 49
Search research articles
Search
Showing results (361-370 of 487) with videos related to
Sort By:
Page
of 49
Nature Medicine
|
August 12, 2022
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial
Vivek Subbiah, Philippe A Cassier, Salvatore Siena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2019
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Razelle Kurzrock, Douglas W Ball, Marianna L Zahurak, et al.
Cancers
|
May 18, 2019
MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
Anthony P Conley, Wei-Lien Wang, John A Livingston, et al.
Cancer Chemotherapy and Pharmacology
|
June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
Journal for Immunotherapy of Cancer
|
April 22, 2017
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Matthew J Reilley, Ann Bailey, Vivek Subbiah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Scientific Reports
|
November 23, 2017
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
Vikas Dembla, Roman Groisberg, Ken Hess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Cancer Research Communications
|
December 21, 2023
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies
Vivek Subbiah, Niamh Coleman, Sarina A Piha-Paul, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2023
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Pashtoon M Kasi, Jessica K Lee, Lincoln W Pasquina, et al.
Page
of 49